Theranostic nanoparticles

Journal of Nuclear Medicine

Volumn 55, Issue 12, 2014, Pages 1919-1922

  Chen, Feng ^a   Ehlerding, Emily B ^b   Cai, Weibo ^a,b,c,d  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c University of Wisconsin Madison   (United States)

^d UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Active targeting; Cancer; Nanomedicine; Theranostic nanoparticle; Theranostics

Indexed keywords

DOXORUBICIN; FOLATE RECEPTOR; FOLIC ACID; GEMCITABINE; GOLD NANOPARTICLE; LIGAND; MACROGOL; MEMBRANE PROTEIN; NANOPARTICLE; SMALL INTERFERING RNA; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TUMOR MARKER; UROKINASE RECEPTOR; VITRONECTIN RECEPTOR; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BIOCOMPATIBILITY; BIODEGRADATION; CARCINOGENESIS; CONTROLLED STUDY; IN VIVO STUDY; METASTASIS; MOLECULAR IMAGING; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; RECEPTOR BINDING; TRANSLATIONAL RESEARCH; TUMOR LOCALIZATION; CHEMISTRY; HUMAN; NEOPLASM; SCINTISCANNING; SYNTHESIS;

HUMANS; NANOPARTICLES; NEOPLASMS; RADIOPHARMACEUTICALS;

EID: 84915767964     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.146019     Document Type: Article

References (24)

1. Jokerst JV, Gambhir SS. Molecular imaging with theranostic nanoparticles. Acc Chem Res. 2011;44:1050-1060.
2. Xie J, Lee S, Chen X. Nanoparticle-based theranostic agents. Adv Drug Deliv Rev. 2010;62:1064-1079.
3. Lammers T, Aime S, Hennink WE, Storm G, Kiessling F. Theranostic nanomedicine. Acc Chem Res. 2011;44:1029-1038.
4. Blackwell KL, Burstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol. 2012;30:2585-2592.
5. Benezra M, Penate-Medina O, Zanzonico PB, et al. Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J Clin Invest. 2011;121:2768-2780.
6. Thakor AS, Gambhir SS. Nanooncology: the future of cancer diagnosis and therapy. CA Cancer J Clin. 2013;63:395-418.
7. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63:136-151.
8. Smith BR, Kempen P, Bouley D, et al. Shape matters: intravital microscopy reveals surprising geometrical dependence for nanoparticles in tumor models of extravasation. Nano Lett. 2012;12:3369-3377.
9. Chen F, Cai W. Tumor vasculature targeting: a generally applicable approach for functionalized nanomaterials. Small. 2014;10:1887-1893.
10. Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev. 2000;41:147-162.
11. Jin CS, Cui L, Wang F, Chen J, Zheng G. Targeting-triggered porphysome nanostructure disruption for activatable photodynamic therapy. Adv Healthc Mater. 2014;3:1240-1249.
12. Yue C, Liu P, ZhengM, et al. IR-780 dye loaded tumor targeting theranostic nanoparticles for NIR imaging and photothermal therapy. Biomaterials. 2013;34:6853-6861.
13. Santra S, Kaittanis C, Grimm J, Perez JM. Drug/dye-loaded, multifunctional iron oxide nanoparticles for combined targeted cancer therapy and dual optical/magnetic resonance imaging. Small. 2009;5:1862-1868.
14. Zhen Z, Tang W, Guo C, et al. Ferritin nanocages to encapsulate and deliver photosensitizers for efficient photodynamic therapy against cancer. ACS Nano. 2013;7:6988-6996.
15. Zhen Z, Tang W, Chen H, et al. RGD-modified apoferritin nanoparticles for efficient drug delivery to tumors. ACS Nano. 2013;7:4830-4837.
16. Xing H, Zheng X, Ren Q, et al. Computed tomography imaging-guided radiotherapy by targeting upconversion nanocubes with significant imaging and radiosensitization enhancements. Sci Rep. 2013;3:1751.
17. Chen Z, Penet MF, Nimmagadda S, et al. PSMA-targeted theranostic nanoplex for prostate cancer therapy. ACS Nano. 2012;6:7752-7762.
18. Lee GY, Qian WP, Wang L, et al. Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer. ACS Nano. 2013;7:2078-2089.
19. von Maltzahn G, Park JH, Lin KY, et al. Nanoparticles that communicate in vivo to amplify tumour targeting. Nat Mater. 2011;10:545-552.
20. Zhen Z, Tang W, Chuang YJ, et al. Tumor vasculature targeted photodynamic therapy for enhanced delivery of nanoparticles. ACS Nano. 2014;8:6004-6013.
21. Bhuniya S, Maiti S, Kim EJ. An activatable theranostic for targeted cancer therapy and imaging. Angew Chem Int Ed Engl 2014;53:4469-4474.
22. Mura S, Couvreur P. Nanotheranostics for personalized medicine. Adv Drug Deliv Rev. 2012;64:1394-1416.
23. Muthu MS, Leong DT, Mei L, Feng S-S. Nanotheranostics: application and further development of nanomedicine strategies for advanced theranostics. Theranostics. 2014;4:660-677.
24. Puri A, Blumenthal R. Polymeric lipid assemblies as novel theranostic tools. Acc Chem Res. 2011;44:1071-1079.